--- title: "Kiniksa Pharmaceuticals International (KNSA) stock" url: "https://aibio.space/companies/kiniksa-pharmaceuticals-international/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA), United Kingdom. The directory classifies it as Pharmaceuticals: Major." --- KNSA Kiniksa Pharmaceuticals International, plc NASDAQ · United Kingdom # Kiniksa Pharmaceuticals International (KNSA) news Distress · 2025-02-25 ## [Kiniksa ends abiprubart Phase 2b trial and terminates mavrilimumab license with MedImmune](https://aibio.space/news/kiniksa-ends-abiprubart-phase-2b-trial-terminates-mavrilimumab-license/) Kiniksa has incurred about $19 million in expenses from ending the Sjögren's trial and expects $14 million to $17 million more. It reported $243.6 million in cash, cash equivalents and short-term investments and no debt, and its 2024 net loss was $43.2 million. ## Latest Kiniksa Pharmaceuticals International news We have not published a story on Kiniksa Pharmaceuticals International yet. When there is news, it will appear here. ## Kiniksa Pharmaceuticals International at a glance - **Ticker**: KNSA - **Listing**: NASDAQ - **Country**: United Kingdom - **Cash, Sep 30, 2026**: $568.8 million ### Related companies - [Shield Therapeutics Plc](https://aibio.space/companies/shield-therapeutics/) LSE: STX - [Bicycle Therapeutics](https://aibio.space/companies/bicycle-therapeutics/) NASDAQ: BCYC - [Venture Life Group Plc](https://aibio.space/companies/venture-life/) LSE: VLG - [Autolus Therapeutics](https://aibio.space/companies/autolus-therapeutics/) NASDAQ: AUTL - [ValiRx](https://aibio.space/companies/valirx/) LSE: VAL - [Haleon](https://aibio.space/companies/haleon/) LSE: HLN - [Biodexa Pharmaceuticals](https://aibio.space/companies/biodexa-pharmaceuticals/) NASDAQ: BDRX - [Coiled Therapeutics Plc](https://aibio.space/companies/coiled-therapeutics/) LSE: COIL ### Also on NASDAQ - [Guardant Health](https://aibio.space/companies/guardant-health/) GH - [WORK Medical Technology Group LTD](https://aibio.space/companies/work-medical-technology/) WOK - [Biomea Fusion](https://aibio.space/companies/biomea-fusion/) BMEA - [Alaunos Therapeutics](https://aibio.space/companies/alaunos-therapeutics/) TCRT - [ACCURAY INC](https://aibio.space/companies/accuray/) ARAY - [GridAI Technologies](https://aibio.space/companies/gridai-technologies/) GRDX ## What Kiniksa Pharmaceuticals International does Kiniksa Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its lead product, ARCALYST, is an interleukin-1α and interleukin-1β cytokine trap that it licensed from Regeneron in 2017. The FDA approved ARCALYST in March 2021 for recurrent pericarditis, and the text says it is also approved in the U.S. for Cryopyrin-Associated Periodic Syndromes (CAPS) and for maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist (DIRA). Kiniksa is responsible for U.S. sales and distribution of ARCALYST and evenly splits profits with Regeneron. Hangzhou Zhongmei Huadong Pharmaceutical holds exclusive rights to develop and commercialize ARCALYST in its territory, granted in 2022. Its investigational KPL-387 is a fully human IgG2 antibody that binds the IL-1 receptor 1, in a Phase 2/3 trial in recurrent pericarditis with potential for monthly subcutaneous self-administration. The company expects data from the Phase 2 portion of that trial in the second half of 2026. It also initiated a collaborative study with The Mayo Clinic and Johns Hopkins University into ARCALYST in cardiac sarcoidosis. | Product or program | What it is | Stage | |---|---|---| | ARCALYST | Interleukin-1 cytokine trap for recurrent pericarditis and CAPS | approved | | KPL-387 | Investigational fully human anti-IL-1R1 antibody for recurrent pericarditis | Phase 2/3 | Summarised from the company's [10-K filed Feb 24, 2026](https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/knsa-20251231x10k.htm). ## Kiniksa Pharmaceuticals International annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$677.6 million](https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/) | [$423.2 million](https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/) | | Research and development | [$96.9 million](https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/) | [$111.6 million](https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/) | | Net income (loss) | [$59.0 million](https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/) | [-$43.2 million](https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/) | | Cash from operations | [$138.0 million](https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/) | [$25.7 million](https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/) | | Cash and equivalents | [$165.6 million](https://www.sec.gov/Archives/edgar/data/1730430/000110465926119186/) | [$183.6 million](https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/) | | Short-term investments | [$248.5 million](https://www.sec.gov/Archives/edgar/data/1730430/000110465926119186/) | [$60.0 million](https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $81.7 million, plus short-term investments of $487.1 million, $568.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Kiniksa Pharmaceuticals International What is the ticker symbol of Kiniksa Pharmaceuticals International? Kiniksa Pharmaceuticals International, plc trades under the ticker KNSA on NASDAQ. Where is Kiniksa Pharmaceuticals International listed? Kiniksa Pharmaceuticals International, plc is listed on NASDAQ. What is the SEC CIK of Kiniksa Pharmaceuticals International? The SEC Central Index Key (CIK) for Kiniksa Pharmaceuticals International, plc is 1730430. Its filings are on SEC EDGAR. Which country or territory is Kiniksa Pharmaceuticals International listed under? Our directory records Kiniksa Pharmaceuticals International, plc under United Kingdom. What does Kiniksa Pharmaceuticals International do? Our directory classifies Kiniksa Pharmaceuticals International, plc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Kiniksa Pharmaceuticals International? The ISIN recorded for Kiniksa Pharmaceuticals International, plc is GB00BRXB0C07. Does aibio.space cover Kiniksa Pharmaceuticals International? aibio.space lists Kiniksa Pharmaceuticals International, plc among 2,820 public biotech companies and publishes its news here as stories appear. What does Kiniksa Pharmaceuticals International develop? Kiniksa Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its lead product, ARCALYST, is an interleukin-1α and interleukin-1β cytokine trap that it licensed from Regeneron in 2017. What is ARCALYST from Kiniksa Pharmaceuticals International? ARCALYST: Interleukin-1 cytokine trap for recurrent pericarditis and CAPS Stage: approved. What is KPL-387 from Kiniksa Pharmaceuticals International? KPL-387: Investigational fully human anti-IL-1R1 antibody for recurrent pericarditis Stage: Phase 2/3. What was Kiniksa Pharmaceuticals International's revenue last year? $677.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Kiniksa Pharmaceuticals International profitable? Kiniksa Pharmaceuticals International, plc reported net income of $59.0 million for the fiscal year ended Dec 31, 2025, and generated $138.0 million of cash from operations, per its annual report to the SEC. How much does Kiniksa Pharmaceuticals International spend on research and development? $96.9 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Kiniksa Pharmaceuticals International have? $568.8 million in cash and short-term investments at Sep 30, 2026, per its 10-Q. What is the latest Kiniksa Pharmaceuticals International (KNSA) stock news? Our latest story on Kiniksa Pharmaceuticals International, dated Feb 25, 2025: "Kiniksa ends abiprubart Phase 2b trial and terminates mavrilimumab license with MedImmune". Kiniksa has incurred about $19 million in expenses from ending the Sjögren's trial and expects $14 million to $17 million more. It reported $243.6 million in cash, cash equivalents and short-term investments and no debt, and its 2024 net loss was $43.2 million. [Source](https://aibio.space/news/kiniksa-ends-abiprubart-phase-2b-trial-terminates-mavrilimumab-license/). ## Investor discussion: Kiniksa Pharmaceuticals International Members talk about Kiniksa Pharmaceuticals International (KNSA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Kiniksa Pharmaceuticals International, newest first. Each line links the filing it comes from. 1. 2025-02-25 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.02,2.02,2.05,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1730430/000110465925016725/tm257489d1_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:KNSA on TradingView](https://www.tradingview.com/symbols/NASDAQ-KNSA/). ## SEC filings and registration - **SEC name**: Kiniksa Pharmaceuticals International, plc - **CIK**: 1730430 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: KNSA (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 105 PICCADILLY, SECOND FLOOR, LONDON, W1J 7NJ - **Phone**: 7814319100 - **Former names**: Kiniksa Pharmaceuticals, Ltd. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000034/knsa-20261017x8k.htm) filed 2026-10-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1730430/000110465926087545/knsa-20260630x10q.htm) filed 2026-07-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000031/knsa-20260728x8k.htm) filed 2026-07-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000029/knsa-20260529x8k.htm) filed 2026-05-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000025/knsa-20260521x8k.htm) filed 2026-05-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000021/knsa-20260430x8k.htm) filed 2026-05-01 - [10-Q](https://www.sec.gov/Archives/edgar/data/1730430/000110465926050359/knsa-20260331x10q.htm) filed 2026-04-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000017/knsa-20260428x8k.htm) filed 2026-04-28 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001730430), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Kiniksa Pharmaceuticals International, plc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker KNSA, recorded under United Kingdom. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Kiniksa Pharmaceuticals International, plc - **Ticker**: KNSA - **Listing**: NASDAQ - **Country or territory**: United Kingdom - **Business scope**: Pharmaceuticals: Major - **ISIN**: GB00BRXB0C07 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-KNSA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/kiniksa-pharmaceuticals-international/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Kiniksa Pharmaceuticals International (KNSA) stock", 2026-10-31, https://aibio.space/companies/kiniksa-pharmaceuticals-international/